biote Corp. (BTMD) vs eXoZymes, Inc. (EXOZ)
A side-by-side comparison of biote Corp. and eXoZymes, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BTMD
biote Corp.
$1.18HealthcareDelayed quote: Oct 6, 2026, 11:34 AM EDT
EXOZ
eXoZymes, Inc.
$5.60HealthcareDelayed quote: Oct 6, 2026, 11:28 AM EDT
Total return — BTMD vs EXOZ
growth of $100 · dividends reinvested · last 2yBTMD -79.7% (-55.0%/yr)EXOZ -36.2% (-20.1%/yr)EXOZ compounded faster over this window
BTMD EXOZ
BTMD vs EXOZ: by the numbers
- •EXOZ is the larger company ($52M vs $52M market cap).
- •BTMD is profitable (3.19% net margin) while EXOZ runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | BTMD | EXOZ |
|---|---|---|
| P/E ratio | 10.07 | N/A |
| P/S ratio | 0.28 | N/A |
| P/B ratio | N/A | 14.22 |
| EV / EBITDA | 9.10 | N/A |
| FCF yield | 37.97% | N/A |
Profitability
| Metric | BTMD | EXOZ |
|---|---|---|
| Gross margin | 71.46% | 0.00% |
| Operating margin | 18.50% | 0.00% |
| Net margin | 3.19% | 0.00% |
| ROE | N/A | -278.89% |
| ROIC | 13.63% | -157.40% |
Growth (annualized)
| Metric | BTMD | EXOZ |
|---|---|---|
| Revenue CAGR (5Y) | 10.52% | N/A |
| EPS CAGR (5Y) | -25.90% | N/A |
| FCF CAGR (5Y) | 3.81% | N/A |
| Total return CAGR (5Y) | -35.12% | N/A |
Frequently asked
- Is BTMD or EXOZ more profitable?
- BTMD runs the higher net margin — BTMD at 3.19% versus EXOZ at 0.00%.
Go deeper
Dig into the metrics
biote P/E ratiobiote ROEeXoZymes ROEbiote operating margineXoZymes operating marginbiote revenue growtheXoZymes revenue growthbiote free cash floweXoZymes free cash flow
biote & eXoZymes appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.